The Government’s Priority Investment in Biotechnology and the Formation of Global Biocommunities
First written in FY2023-Q1. 4 of 6 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2026.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Currently, 25 regenerative medicine products have been approved in Japan, including 5 for which the company has obtained approval.」
The company explained that the number of approved regenerative medicine products in Japan increased from the previously reported 21 to 25, and that it holds approval for 5 products. - FY2026-H1AdvancedAnnual report
「In the regenerative medicine and cell therapy fields, as of 30 September 2025, 21 products, including the company's 5 products, had received marketing authorization, and social expectations continue to grow.」
The company explained that the number of approved regenerative medicine products in Japan increased from the previously reported 19 to 21. - FY2024RestatedAnnual report
「The Ministry of Economy, Trade and Industry decided to provide a total of ¥5 billion in subsidies under the FY2022 supplementary budget program “Project for Creating an Environment for the Social Implementation of Regenerative, Cellular and Gene Therapies,” and the company's initiative was selected as one of the projects.」
The company continues to describe the government's priority investment in regenerative, cellular and gene therapies and the selection of its initiative as part of its business environment. - FY2024-Q3AdvancedAnnual report
「In November 2023, the Keidanren Bioeconomy Committee published an opinion paper titled “Strengthening the Biopharmaceutical Industry: Promoting and Industrializing Regenerative Medicine Products,” organizing the issues in this field from the industry's perspective. Through these activities, the number of regenerative medicine products in Japan, including the company's 5 products, reached 20.」
Regarding regenerative medicine products, the company newly described the publication by Keidanren of an opinion paper on strengthening the industry and the increase in domestically approved products to 20, including 5 of the company's products. - FY2024-Q1AdvancedAnnual report
「The Ministry of Economy, Trade and Industry decided to provide a total of ¥5 billion in subsidies under the FY2022 supplementary budget program “Project for Creating an Environment for the Social Implementation of Regenerative, Cellular and Gene Therapies,” and the company's initiative was selected as one of the projects.」
Regarding the government's priority investment in regenerative, cellular and gene therapies, the company specifically described the Ministry of Economy, Trade and Industry's ¥5 billion subsidy program and the selection of its initiative. - FY2023-Q1First statedAnnual report
「Against this backdrop, in Japan, the Kishida Cabinet proposed the “Grand Design and Action Plan for a New Form of Capitalism,” which includes policies to promote growth in the biotechnology sector, including priority investment in science, technology and innovation covering regenerative, cellular and gene therapies. In addition, to realize the world's most advanced bioeconomy society by 2030, the Cabinet Office is promoting the formation of bio communities as a strategy for entering global markets in this field, and has certified the Tokyo and Kansai regions as “Global Bio Communities.”」
The company newly described as part of its business environment the government's priority investment in regenerative, cellular and gene therapies under its growth policies, together with the formation and regional certification of bio communities toward 2030.